- New Purchases: CI, GH, HPR, SYNH, ASND, FOLD, PFE, ARRY, RDUS, BNFT, ZLAB, PBYI, MDCO, KURA,
- Added Positions: HUM, EVH, TDOC, BMY, QGEN, ISRG, ALGN, ANTM, QDEL, WCG, DXCM, ABMD, NKTR, ABT, HCM, IART, GMED, VCRA, ALNY, OXFD, LIVN, BSX, INGN, BAX, XENT, ZBH, CSLT, NVRO, OMCL, BGNE, IRTC, GNMK, MOH, REGN, HMSY, ALDR, ALXN, STIM, INSP, BDX, ILMN, ESPR, VEEV, QURE, TNDM, HCA, QTRX, TRHC, MDSO, CVS, BLUE, PTLA, AKCA, DHR, AMED, GWPH, EXEL, ARGX, JAZZ, FGEN, MTLS, SAGE, PRAH, EW, SGEN, IDXX, ARNA, RGNX, WBA, PINC, PTCT, RARE, TMO, VRTX, ABC, FIT, ACAD, AMRX,
- Reduced Positions: CELG, AMGN, BIIB, IONS, MGNX, WMGI, GILD, CDNA, INSM, MYL, SUPN, NBIX, MDT, INCY, ICPT, SRPT, CHRS, MRTX, CNC, SYK, QTNT, MCK, RMD, LH, PEN, HSIC, VAR, AFMD,
- Sold Out: BMRN, LGND, HZNP, CERN, AGN, ENDP, LOXO, MYGN, TEVA, IRWD, CLLS, ADAP, CVET, XLRN, ITCI, HCSG, VYGR, NTLA, IOVA,
For the details of Bellevue Group AG's stock buys and sells, go to https://www.gurufocus.com/guru/bellevue+group+ag/current-portfolio/portfolio
These are the top 5 holdings of Bellevue Group AG- Align Technology Inc (ALGN) - 334,679 shares, 5.28% of the total portfolio. Shares added by 7.68%
- Intuitive Surgical Inc (ISRG) - 150,999 shares, 4.78% of the total portfolio. Shares added by 8.79%
- Abbott Laboratories (ABT) - 1,040,587 shares, 4.61% of the total portfolio. Shares added by 6.57%
- Illumina Inc (ILMN) - 257,696 shares, 4.44% of the total portfolio. Shares added by 2.30%
- Teladoc Health Inc (TDOC) - 1,374,294 shares, 4.24% of the total portfolio. Shares added by 27.98%
Bellevue Group AG initiated holding in Cigna Corp. The purchase prices were between $159.69 and $199.81, with an estimated average price of $183.17. The stock is now traded at around $155.27. The impact to a portfolio due to this purchase was 1.48%. The holding were 165,657 shares as of .
New Purchase: Guardant Health Inc (GH)Bellevue Group AG initiated holding in Guardant Health Inc. The purchase prices were between $34.3 and $97.98, with an estimated average price of $54.87. The stock is now traded at around $77.45. The impact to a portfolio due to this purchase was 0.47%. The holding were 109,652 shares as of .
New Purchase: Horizon Therapeutics PLC (HPR)Bellevue Group AG initiated holding in Horizon Therapeutics PLC. The purchase prices were between $16.5 and $25.2, with an estimated average price of $20.53. The stock is now traded at around $23.60. The impact to a portfolio due to this purchase was 0.23%. The holding were 158,800 shares as of .
New Purchase: Syneos Health Inc (SYNH)Bellevue Group AG initiated holding in Syneos Health Inc. The purchase prices were between $36.91 and $55.7, with an estimated average price of $48.45. The stock is now traded at around $43.42. The impact to a portfolio due to this purchase was 0.14%. The holding were 47,200 shares as of .
New Purchase: Ascendis Pharma A/S (ASND)Bellevue Group AG initiated holding in Ascendis Pharma A/S. The purchase prices were between $62.15 and $129.99, with an estimated average price of $86.75. The stock is now traded at around $121.81. The impact to a portfolio due to this purchase was 0.12%. The holding were 18,200 shares as of .
New Purchase: Amicus Therapeutics Inc (FOLD)Bellevue Group AG initiated holding in Amicus Therapeutics Inc. The purchase prices were between $9.58 and $13.92, with an estimated average price of $12.16. The stock is now traded at around $12.54. The impact to a portfolio due to this purchase was 0.11%. The holding were 150,000 shares as of .
Added: Humana Inc (HUM)Bellevue Group AG added to a holding in Humana Inc by 93.84%. The purchase prices were between $262.61 and $310.3, with an estimated average price of $288.61. The stock is now traded at around $243.68. The impact to a portfolio due to this purchase was 1.09%. The holding were 152,477 shares as of .
Added: Evolent Health Inc (EVH)Bellevue Group AG added to a holding in Evolent Health Inc by 3010.75%. The purchase prices were between $12.17 and $20.92, with an estimated average price of $15.96. The stock is now traded at around $14.22. The impact to a portfolio due to this purchase was 0.95%. The holding were 1,408,237 shares as of .
Added: Teladoc Health Inc (TDOC)Bellevue Group AG added to a holding in Teladoc Health Inc by 27.98%. The purchase prices were between $46.23 and $69.99, with an estimated average price of $61.02. The stock is now traded at around $59.10. The impact to a portfolio due to this purchase was 0.93%. The holding were 1,374,294 shares as of .
Added: Bristol-Myers Squibb Company (BMY)Bellevue Group AG added to a holding in Bristol-Myers Squibb Company by 42.93%. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $46.63. The impact to a portfolio due to this purchase was 0.55%. The holding were 695,824 shares as of .
Added: Qiagen NV (QGEN)Bellevue Group AG added to a holding in Qiagen NV by 41.79%. The purchase prices were between $33.78 and $40.68, with an estimated average price of $37.87. The stock is now traded at around $37.25. The impact to a portfolio due to this purchase was 0.41%. The holding were 617,194 shares as of .
Added: WellCare Health Plans Inc (WCG)Bellevue Group AG added to a holding in WellCare Health Plans Inc by 29.10%. The purchase prices were between $230.61 and $282.5, with an estimated average price of $258.4. The stock is now traded at around $272.85. The impact to a portfolio due to this purchase was 0.36%. The holding were 107,419 shares as of .
Sold Out: Biomarin Pharmaceutical Inc (BMRN)Bellevue Group AG sold out a holding in Biomarin Pharmaceutical Inc. The sale prices were between $84.2 and $98.62, with an estimated average price of $92.66.
Sold Out: Ligand Pharmaceuticals Inc (LGND)Bellevue Group AG sold out a holding in Ligand Pharmaceuticals Inc. The sale prices were between $105.93 and $142.47, with an estimated average price of $121.61.
Sold Out: Horizon Therapeutics PLC (HZNP)Bellevue Group AG sold out a holding in Horizon Therapeutics PLC. The sale prices were between $19.49 and $29.01, with an estimated average price of $23.59.
Sold Out: Cerner Corp (CERN)Bellevue Group AG sold out a holding in Cerner Corp. The sale prices were between $50.7 and $58.82, with an estimated average price of $55.63.
Sold Out: Allergan PLC (AGN)Bellevue Group AG sold out a holding in Allergan PLC. The sale prices were between $132.09 and $160.79, with an estimated average price of $144.95.
Sold Out: Loxo Oncology Inc (LOXO)Bellevue Group AG sold out a holding in Loxo Oncology Inc. The sale prices were between $131.02 and $234.75, with an estimated average price of $222.49.
Here is the complete portfolio of Bellevue Group AG. Also check out:
1. Bellevue Group AG's Undervalued Stocks
2. Bellevue Group AG's Top Growth Companies, and
3. Bellevue Group AG's High Yield stocks
4. Stocks that Bellevue Group AG keeps buying
